CytomX Therapeutics, Inc. (CTMX) Major Shareholder Robert I. Tepper Sells 24,777 Shares
CytomX Therapeutics, Inc. (NASDAQ:CTMX) major shareholder Robert I. Tepper sold 24,777 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total transaction of $603,072.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of CytomX Therapeutics, Inc. (NASDAQ CTMX) traded down 3.9952% during mid-day trading on Thursday, hitting $22.1675. 418,461 shares of the stock traded hands. The stock has a 50 day moving average price of $16.92 and a 200-day moving average price of $15.62. The company’s market cap is $817.25 million. CytomX Therapeutics, Inc. has a one year low of $9.85 and a one year high of $24.67.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The firm had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. On average, analysts forecast that CytomX Therapeutics, Inc. will post ($1.49) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/cytomx-therapeutics-inc-ctmx-major-shareholder-robert-i-tepper-sells-24777-shares/1610506.html.
Large investors have recently modified their holdings of the company. Legal & General Group Plc grew its holdings in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,434 shares during the period. First Quadrant L P CA purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $160,000. Goldman Sachs Group Inc. purchased a new stake in shares of CytomX Therapeutics during the 1st quarter worth about $190,000. Cubist Systematic Strategies LLC purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $174,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of CytomX Therapeutics during the 1st quarter worth about $206,000. Institutional investors and hedge funds own 59.97% of the company’s stock.
Several brokerages have weighed in on CTMX. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Nomura increased their price target on shares of CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research report on Wednesday. Cowen and Company reissued an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday. Bank of America Corporation reissued a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Finally, Cann reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.67.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.